Celecoxib for the Treatment of Pain in Osteoarthritis and Rheumatoid Arthritis [printed text] / Carmen Moga, Author ; Christa Harstall, Author ; Zhiliu Tang, Author . - Alberta [Canada] : Institute of Health Economics, 2005 . - viii, 72 p. : ill. ; A4. - ( Information Paper, ISSN 1706-7863; 24) . ISSN : 1-894827-12-5 : 0 € Languages : English ( eng)
| Descriptors: |
Indexation
Anti-Inflammatory Agents, Non-Steroidal ; Arthritis, Rheumatoid ; drug therapy ; Therapeutics
Classification
WB 330 Drug therapy
|
| Abstract: |
Overall, short-term use of celecoxib was equivalent to non-selective NSAIDs (naproxen and diclofenac) and other COX-2 inhibitors (nimesulide and rofecoxib) and was superior to acetaminophen in reducing pain and improving function for patients with RA and OA. Short-term use of celecoxib was associated with a reduction in rates of gastroduodenal erosions or ulcers compared with those for non-selective NSAIDs (naproxen, ibuprofen, and diclofenac) in patients with RA and OA. Many questions remain to be addressed about the long-term safety of celecoxib compared with non-selective NSAIDs and about the combination treatment of NSAIDs and other types of drugs. Health Canada recommended usage restrictions for Celebrex beginning in April 2005. Celebrex should not be used in patients who have had a heart attack or stroke, serious chest pain related to hearth disease, or congestive heart failure. Celebrex may increase the risk of cardiovascular events in patients with high blood pressure, high cholesterol, diabetes, and smoking. Also, Celebrex should be prescribed and used at the lowest possible dose and for the shortest, necessary period of time. |
| Contents note: |
ACKNOWLEDGEMENTS . I -- EXECUTIVE SUMMARY . III -- ABBREVIATIONS . V -- SCOPE .1 -- BACKGROUND.2 -- EPIDEMIOLOGICAL AND CLINICAL ASPECTS .3 -- COX-2 INHIBITORS .4 -- EVIDENCE FROM SRS .6 -- Efficacy/effectiveness .8 -- Safety ..8 -- EVIDENCE FROM RCTS .12 -- Efficacy/effectiveness .16 -- Safety .17 -- REGULATION STATUS AND POST-MARKETING DATA.20 -- Health Canada and FDA regulatory status .20 -- Labeling and public health alerts in the United States, Canada, and Australia .21 -- Post-marketing data in Canada .22 -- POSITION PAPERS AND GUIDELINES .24 -- COST AND MARKETING .26 -- DISCUSSION .28 -- SRs on celecoxib .28 -- RCTs on celecoxib .28 -- Future research .29 -- Clinical relevance .30 -- CONCLUSION .33 -- REFERENCES .34 -- APPENDIX A: SEARCH AND METHODOLOGY .41 -- APPENDIX B.1: SYSTEMATIC REVIEWS ON EFFICACY/EFFECTIVENESS AND SAFETY .54 -- APPENDIX B.2: RCTS ON EFFICACY/EFFECTIVENESS AND SAFETY .58 -- APPENDIX C: STUDIES (RCTS) ON CELECOXIB FOR OA AND RA INCLUDED IN THE SYSTEMATIC REVIEWS .62 -- APPENDIX D: QUALITY ASSESSMENT CHECKLIST FOR SYSTEMATIC REVIEWS .66 -- APPENDIX E: EXCLUDED SYSTEMATIC REVIEWS AND RANDOMIZED CONTROLLED STUDIES .71 -- Tables and Figures -- FIGURE 1: NUMBER NEEDED TO HARM (NNH) .32 -- TABLE 1: CYCLO-OXYGENASE SELECTIVITY OF COX-2 SELECTIVE AND NON-SELECTIVE NSAIDS (IN VITRO DETERMINATIONS) .5 -- TABLE 2: SUMMARY OF SYSTEMATIC REVIEWS .7 -- TABLE 3: SUMMARY OF RCTS .13 -- TABLE 4: LICENSURE AND INDICATIONS IN CANADA AND THE UNITED STATES .20 -- TABLE 5: POSITION PAPERS AND GUIDELINES ON THE USE OF COX-2 INHIBITORS FOR RA AND OA .25 -- TABLE A.1: DATABASES AND SEARCH TERMS USED IN THE SEARCH STRATEGY (MARCH 2004) .42 -- TABLE A.2: DATABASES AND SEARCH TERMS USED IN THE UPDATED SEARCH STRATEGY (NOVEMBER 2004) .45 -- TABLE A.3: EFFICACY/EFFECTIVENESS OUTCOME MEASURES .51 -- TABLE A.4: SAFETY OUTCOME MEASURES .52 -- TABLE B.1.1: EFFICACY/EFFECTIVENESS OF CELECOXIB FOR THE TREATMENT OF RA .54 -- TABLE B.1.2: SAFETY OF CELECOXIB FOR THE TREATMENT OF OA AND RA .55 -- TABLE B.2.1: EFFICACY/EFFECTIVENESS AND SAFETY OF CELECOXIB FOR THE TREATMENT OF OA AND RA .58 -- TABLE C.1: STUDIES (RCTS) ON CELECOXIB FOR OA AND RA INCLUDED IN THE SYSTEMATIC REVIEWS .62 -- TABLE D.1: CRITICAL APPRAISAL OF REVIEWS .69 -- TABLE E.1: EXCLUDED SYSTEMATIC REVIEWS .71 -- TABLE E.2: EXCLUDED RANDOMIZED CONTROLLED STUDIES .72 |
| Link for e-copy: |
http://www.ihe.ca/publications/library/archived/celecoxib-for-the-treatment-of-p [...] |
| Format of e-copy: |
PDF (553 KB) |
| Record link: |
https://kce.docressources.info/index.php?lvl=notice_display&id=1761 |
|  |
Add the result to your basket Make a suggestion Refine your search Apply to external sourcesCelecoxib for the Treatment of Pain in Osteoarthritis and Rheumatoid Arthritis / Carmen Moga / Alberta [Canada] : Institute of Health Economics (2005)
